Skip to content

The effect of DISTREPTAZA onIVF outcome in endometriosis

Comparison the impact of DISTREPTAZA and a placebo on IVF outcomes after laparoscopic surgery in cases of endometriosis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20091012002576N43
Enrollment
40
Registered
2024-06-17
Start date
2024-07-06
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis , infertility. Female infertility of other origin

Interventions

Intervention 1: Intervention group: Following laparoscopy for endometriosis, participants are prescribed suppository rectal distreptaza 2g for 9 days,(3 days,TDS, 3days BD,3 days daily) , after which

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: Approved endometriosis by pathology Presence good quality embryo age 20-38 y/o

Exclusion criteria

Exclusion criteria: Hypersensitivity to distreptaza BMI>30 Diabetes melitus Hydrosalpinx Severe male factor AMH<1

Design outcomes

Primary

MeasureTime frame
Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: Lab test for Bhcg titer.;Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: Visualisation of fetal heart activity in transvaginal sonogram.;Time to pregnancy. Timepoint: Weeks after surgery till pregnancy. Method of measurement: Weeks.;Endometrial thickness and grade. Timepoint: At day of starting progesterone. Method of measurement: Transvaginal sonogram.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026